A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial for Adult Evaluation of the Efficacy and Safety of a Sars-Cov-2 Recombinant Spike Rbd Protein Vaccine (Abdala-3 Study)
Author(s) -
Francisco Hernández-Bernal,
Maria del Carmen Ricardo-Cobas,
Yenima Martín-Bauta,
Ernesto Rodríguez-Martínez,
Klaudia Urrutia-Pérez,
Karen Urrutia-Pérez,
Joel Quintana-Guerra,
Zadis Navarro-Rodríguez,
Marjoris Piñera-Martínez,
José L. Rodríguez-Reinoso,
Cristina Olimpia Chávez-Chong,
Idania Baladrón-Castrillo,
Grettel Melo-Suárez,
Alejandro Batista-Izquierdo,
Alexis R. Pupo-Micó,
Ricardo L. Mora-Betancourt,
Dayamí Soler-Cano,
Jacqueline Bizet-Almeida,
Maria C. Martínez-Rodríguez,
Leonardo Lobaina-Lambert,
Vivian M. Velázquez-Pérez,
Jalimy Soler-Díaz,
Yunaili Blanco-Garrido,
Sandra Laurencio-Vallina,
Tamara Meriño-Hechavarría,
Norberto Carmenaty-Campos,
Enri Rodríguez-Montero,
Miladys Limonta-Fernández,
Marel A. Valdés,
Reinier Hernández-Rodríguez,
Eulogio Pimentel-Vázquez,
Karem M. Catasús-Álvarez,
Maria V. Cabrera-Núñez,
Marta Ayala-Ávila,
Verena L. Muzio-González,
ABDALA Group of Investigators
Publication year - 2022
Publication title -
ssrn electronic journal
Language(s) - English
Resource type - Journals
ISSN - 1556-5068
DOI - 10.2139/ssrn.4213351
Subject(s) - placebo , medicine , recombinant dna , clinical trial , double blind , vaccine trial , spike (software development) , virology , covid-19 , biology , pathology , genetics , alternative medicine , disease , computer science , infectious disease (medical specialty) , software engineering , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom